Profile: Sanofi SA (SNY.N)
28 Apr 2017
Sanofi, incorporated on May 11, 1994, is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other.
The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. Its pharmaceuticals portfolio consists of flagship products, plus a range of prescription medicines, generic medicines, and Consumer Healthcare products. The Pharmaceuticals segment also includes all associates whose activities are related to pharmaceuticals, in particular Regeneron Pharmaceuticals, Inc. and the entities majority owned by Bristol-Myers Squibb (BMS). The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations.
The Company's Rare Diseases business is focused on products for the treatment of rare genetic diseases and other rare chronic debilitating diseases, including lysosomal storage disorders (LSDs), a group of metabolic disorders caused by enzyme deficiencies. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. Cerezyme (imiglucerase for injection) is an enzyme replacement therapy used to treat Gaucher disease, an inherited, potentially life-threatening LSD. The principal markets for Cerezyme are the United States, Europe and Latin America. Cerdelga (eliglustat) is an oral therapy for Gaucher disease Type I. The principal market for Cerdelga is the United States. Myozyme and Lumizyme (alglucosidase alfa) are enzyme replacement therapies used to treat Pompe disease, an inherited, progressive and often fatal LSD. Fabrazyme (agalsidase beta) is an enzyme replacement therapy used to treat Fabry disease, an inherited, progressive and potentially life threatening LSD. Aldurazyme (laronidase) is a human recombinant enzyme therapy used for the treatment of mucopolysaccharidosis type I (MPS I).
The Company's franchise consists of Aubagio (teriflunomide), a once-daily, oral immunomodulator, and Lemtrada (alemtuzumab), a monoclonal antibody. Aubagio (teriflunomide), a small molecule immunomodulatory agent with anti-inflammatory properties, reversibly inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme involved in the de novo pyrimidine synthesis required for activated lymphocytes to multiply. Lemtrada (alemtuzumab) is a humanized monoclonal antibody.
The Company's Oncology products include Jevtana, Taxotere, Eloxatin, Thymoglobulin, Mozobil and Zaltrap. Jevtana (cabazitaxel), a cytotoxic agent, is a semi-synthetic taxane promoting tubulin assembly and stabilizing microtubules, approved in combination with prednisone for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen. Taxotere (docetaxel), a taxoid class derivative, inhibits cancer cell division by essentially freezing the cell's internal skeleton, which consists of microtubules. Eloxatin (oxaliplatin) is a platinum-based cytotoxic agent. Thymoglobulin (anti-thymocyte Globulin) is a polyclonal anti-human thymocyte antibody preparation that acts as an immunosuppressive and immunomodulating agent. Mozobil (plerixafor injection) is a hematopoietic stem cell mobilizer indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Zaltrap (aflibercept/ziv-aflibercept) is a recombinant fusion protein which acts as a soluble decoy receptor that binds to Vascular Endothelial Growth Factor-A (VEGF-A), Vascular Endothelial Growth Factor-B (VEGF-B) and placental growth factor (PIGF), preventing the bound VEGF from binding to their native receptors.
The Company's diabetes products include Lantus and Toujeo, long acting analogs of human insulin; Apidra, a rapid acting analog of human insulin; Insuman, a range of human insulin; Lyxumia (lixisenatide), a once-daily injectable prandial glucagon-like peptide-1 (GLP-10 receptor agonist, and Soliqua 100/33/Suliqua, an injectable once-daily insulin glargine and lixisenatide combination. Apidra is indicated for the treatment of adults with type I or type II diabetes for supplementary glycemic control. Insuman (human insulin) is a range of insulin solutions and suspensions for injection and is indicated for diabetes patients when treatment with insulin is required.
The Company's Cardiovascular Diseases products include Praluent and Multaq. Praluent (alirocumab) is a human monoclonal antibody (mAb) that blocks the interaction of proprotein convertase subtilisin/kexin type 9 (PCSK9) with low-density lipoprotein (LDL) receptors, increasing the recycling of LDL receptors and reducing LDL cholesterol levels. Multaq (dronedarone) is an oral multichannel blocker with anti-arrhythmic properties for prevention of atrial fibrillation recurrences.
The Company's Established Prescription Products include Plavix or Iscover, Lovenox/Clexane, Aprovel/Avapro/Karvea, Renagel and Renvela, Allegra/Telfast, Stilnox/Ambien/Myslee, Synvisc/ Synvisc-One, and Depakine. Plavix or Iscover (clopidogrel bisulfate), a platelet adenosine diphosphate (ADP) receptor antagonist with an onset of action that selectively inhibits platelet aggregation induced by ADP, is indicated for the prevention of atherothrombotic events in patients with a history of recent myocardial infarction (MI), recent ischemic stroke or established peripheral arterial disease (PAD). Lovenox or Clexane (enoxaparin sodium) is registered for a range of clinical indications than any other low molecular weight heparin (LMWH). Aprovel or Avapro or Karvea (irbesartan) is an anti-hypertensive belonging to the class of angiotensin II receptor antagonists. Renagel (sevelamer hydrochloride) and Renvela (sevelamer carbonate) are oral phosphate binders used by chronic kidney disease (CKD) patients on dialysis, as well as late stage CKD patients in Europe to treat a condition called hyperphosphatemia, or elevated phosphorus levels, which is associated with heart and bone disease. Allegra or Telfast (fexofenadine hydrochloride) is a long-lasting (12- and 24-hour) non-sedating prescription anti-histamine for the treatment of seasonal allergic rhinitis (hay fever) and uncomplicated hives. Stilnox (zolpidem tartrate) is indicated for the short-term treatment of insomnia. Synvisc and Synvisc-One (hylan G-F 20) are viscosupplements used to treat pain associated with osteoarthritis. The Company's Consumer Healthcare products include Allegra, Nasacort, Doliprane, No-Spa, Enterogermina, Essentiale, Maalox, and Magne B6.
The Company, through Sanofi Pasteur, offers a range of vaccines. In the United States, Sanofi Pasteur produces influenza and meningitis vaccines. In Europe, Sanofi Pasteur's vaccine products are developed and marketed by Sanofi Pasteur MSD (SPMSD), a joint venture. Its products include primary and booster pediatric vaccines for diphtheria, tetanus, pertussis, polio and Hib, such as Pediacel, Pentavac, Repevax, Revaxis, Tetravac, and Imovax Polio; two 6-in-1 combination pediatric vaccines marketed as Hexyon and Vaxelis; the influenza vaccines Vaxigrip/Mutagrip; travel vaccines for hepatitis A, typhoid and yellow fever marketed as Avaxim, Typhim VI, Stamaril and Viatim, and the rabies vaccines Verorab and Imovax Rabies.
Sanofi Pasteur offers Pediatric, Combination and Poliomyelitis (Polio) Vaccines, including Pentaxim, Hexaxim, Pentacel, Act-HIB, Quadracel and Shan5; Influenza Vaccines, such as Fluzone High-Dose vaccine, Fluzone Quadrivalent, Intradermal (ID) trivalent influenza vaccines, and Vaxigrip; Adult and Adolescent Boosters, such as Adacel and Repevax; Meningitis and Pneumonia Vaccines, which includes Menactra; Travel and Endemic Vaccines, such as Shanchol and IMOJEV, and Dengue Vaccines, such as Dengvaxia.
The Company competes with Novo Nordisk, Boehringer Ingelheim, Merck & Co., Inc., Eli Lilly and Company, Bristol-Myers Squibb, Novartis, Shire, Pfizer, Biogen, Teva Pharmaceuticals Industries, Bayer, Roche, Johnson & Johnson, AstraZeneca, Amgen, Reckitt Benckiser, Mylan, Actavis and GlaxoSmithKline.
54 rue la Boetie
Company Web Links
- UPDATE 2-Sanofi beats profit forecasts, upbeat on prospects for eczema drug
- BRIEF-Regeneron and Sanofi announce Kevzara license application resubmission for review by FDA
- BRIEF-Regeneron says FDA approved for praluent injection
- BRIEF-Sanofi Genzyme announces positive new six-year data from analysis of lemtrada
- BRIEF-Sanofi and Regeneron announce FDA approval of a once-monthly dosing option for Praluent